Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the completion of the sale, the chief executive officer owned 591,656 shares of the company’s stock, valued at approximately $16,246,873.76. This trade represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Heartflow Price Performance

HTFL opened at $27.30 on Wednesday. The firm has a 50 day simple moving average of $30.26. The firm has a market cap of $2.32 billion and a price-to-earnings ratio of -15.08. Heartflow, Inc. has a 12-month low of $25.38 and a 12-month high of $41.22.

Hedge Funds Weigh In On Heartflow

A number of hedge funds have recently modified their holdings of the business. Baillie Gifford & Co. bought a new position in shares of Heartflow in the third quarter valued at approximately $101,182,000. New York State Common Retirement Fund bought a new position in Heartflow during the 3rd quarter valued at $4,015,000. Emerald Mutual Fund Advisers Trust purchased a new position in Heartflow during the 3rd quarter worth $4,418,000. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Heartflow in the 3rd quarter worth $10,510,000. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of Heartflow in the third quarter valued at about $982,000.

Analyst Ratings Changes

A number of research analysts have commented on HTFL shares. Canaccord Genuity Group increased their price objective on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. JPMorgan Chase & Co. upped their price target on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Wells Fargo & Company started coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective for the company. Finally, Stifel Nicolaus lifted their price target on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Heartflow has an average rating of “Moderate Buy” and an average target price of $38.50.

Heartflow News Summary

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Analyst upgrades and bullish price-target revisions remain on the tape (Wells Fargo started coverage with an “overweight”; Canaccord, JPMorgan and Stifel have raised targets toward ~$38–$40), supporting medium-term upside expectations.
• Neutral Sentiment: Several smaller institutional investors added positions in recent quarters — a modest vote of confidence but not large enough to offset other flows on its own.
• Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at an average $27.46 (~$619.6k). Insider sales by the CEO can signal liquidity-taking and often weigh on sentiment. CEO Form 4
• Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), reducing her stake ~18%, which adds to negative insider-selling optics. Director Form 4
• Negative Sentiment: Reported large shareholder sell-off (headline noting ~$56.1M in stock sold) increases supply and likely pressured the share price. Major Shareholder Sale
• Negative Sentiment: Short interest surged in January to ~4.95M shares (up ~42% from mid‑January), representing ~5.8% of shares outstanding and ~5.9 days-to-cover — a material rise that can amplify downward moves as traders increase bearish positioning.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.